Auvelity: A New Era in Medicine - Unraveling the Multifaceted Benefits of Dextromethorphan/Bupropion Combination
Current Drug Therapy September 1, 2024 Anchal Dhawan, Sunayna Choudhary, Sumeet Gupta et al.
Auvelity, a newly FDA-approved oral medication combining dextromethorphan (45 mg) and bupropion (105 mg), shows statistically significant antidepressant effects as early as one week compared to placebo, making it the first oral drug with such rapid onset. Its mechanism involves NMDA receptor blockade and sigma-1 receptor agonism, similar to Alzheimer's disease medications like Memantine, suggesting potential to manage agitation in Alzheimer's patients. The drug offers a multi-dimensional approach for treating major depressive disorder and possibly Alzheimer's-related symptoms, with a low-risk profile.